Saturday, September 5, 2026
ExploreSearch
Via News

Agentic AI Systems

2 articles

Salesforce Agentforce Crosses $1B ARR, Marking Enterprise Agentic AI's Shift to Core Operations

Salesforce Agentforce Crosses $1B ARR, Marking Enterprise Agentic AI's Shift to Core Operations

Salesforce Agentforce has surpassed $1B in annual recurring revenue, signaling that enterprise agentic AI has moved beyond pilots into mainstream budget allocation. The concurrent Salesforce-Informatica acquisition underscores that data infrastructure is now the primary competitive bottleneck. Enterprise platforms with integrated AI agents are positioned to capture outsized market share, while per-seat SaaS vendors without agent strategies face multiple compression.

LM Salvado•
MercadoLibre Builds Agentic AI Tools as Finance Pilot Deploys Algorithmic Trading Platform

MercadoLibre Builds Agentic AI Tools as Finance Pilot Deploys Algorithmic Trading Platform

MercadoLibre is investing heavily in proprietary agentic AI systems while Finance Pilot launched an SSL-secured algorithmic trading platform with live performance tracking. Pelican has processed over one billion transactions across global banking standards, signaling production-ready AI deployment in fintech infrastructure.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com